WO2008024408A3 - Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation - Google Patents

Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation Download PDF

Info

Publication number
WO2008024408A3
WO2008024408A3 PCT/US2007/018585 US2007018585W WO2008024408A3 WO 2008024408 A3 WO2008024408 A3 WO 2008024408A3 US 2007018585 W US2007018585 W US 2007018585W WO 2008024408 A3 WO2008024408 A3 WO 2008024408A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
application
cannabinoids
pharmaceutical formulations
cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/018585
Other languages
English (en)
Other versions
WO2008024408A2 (fr
Inventor
Najib Babul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Relmada Therapeutics Inc
Original Assignee
Theraquest Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraquest Biosciences Inc filed Critical Theraquest Biosciences Inc
Publication of WO2008024408A2 publication Critical patent/WO2008024408A2/fr
Publication of WO2008024408A3 publication Critical patent/WO2008024408A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques d'agonistes des cannabinoïdes destinées à être appliquées sur la peau et leur utilisation pour empêcher ou minimiser le risque qu'un abus d'agonistes des cannabinoïdes et/ou que la toxicité des agonistes des cannabinoïdes soit masqué intentionnellement ou non. La présente invention concerne également un procédé consistant à empêcher ou minimiser le risque qu'un abus d'agonistes des cannabinoïdes et/ou que la toxicité des agonistes des cannabinoïdes soit masqué intentionnellement ou non.
PCT/US2007/018585 2006-08-22 2007-08-22 Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation Ceased WO2008024408A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US83911706P 2006-08-22 2006-08-22
US83911506P 2006-08-22 2006-08-22
US60/839,115 2006-08-22
US60/839,117 2006-08-22
US84096906P 2006-08-30 2006-08-30
US84097106P 2006-08-30 2006-08-30
US60/840,969 2006-08-30
US60/840,971 2006-08-30

Publications (2)

Publication Number Publication Date
WO2008024408A2 WO2008024408A2 (fr) 2008-02-28
WO2008024408A3 true WO2008024408A3 (fr) 2008-10-23

Family

ID=39107387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018585 Ceased WO2008024408A2 (fr) 2006-08-22 2007-08-22 Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation

Country Status (1)

Country Link
WO (1) WO2008024408A2 (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8772318B2 (en) * 2008-11-14 2014-07-08 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
DE102009036485B4 (de) * 2009-08-07 2012-10-04 Lts Lohmann Therapie-Systeme Ag Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
ES2842407T3 (es) 2010-12-22 2021-07-14 Syqe Medical Ltd Sistema de administración de fármacos
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
EP2968259B1 (fr) 2013-03-14 2022-09-14 SC Laboratories Inc. Concentrés bioactifs et leurs utilisations
PL3096746T3 (pl) * 2014-01-22 2019-09-30 4P Therapeutics Systemy transdermalne zapobiegające nadużywaniu i niewłaściwemu użyciu
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
RU2721064C2 (ru) 2014-06-30 2020-05-15 Сике Медикал Лтд. Ингалятор с регулированием потока
IL273507B2 (en) 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for administering active substances through the lungs
ES2904293T3 (es) 2014-06-30 2022-04-04 Syqe Medical Ltd Dispositivo para vaporización e inhalación de sustancias aisladas
WO2016001925A1 (fr) 2014-06-30 2016-01-07 Syqe Medical Ltd. Cartouche de dose de médicament pour un dispositif d'inhalateur
ES2898173T3 (es) 2014-06-30 2022-03-04 Syqe Medical Ltd Dispositivos y sistemas para la administración pulmonar de principios activos
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
WO2016123406A1 (fr) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Procédés et systèmes d'administration de médicament
ES2860452T3 (es) * 2015-02-16 2021-10-05 Apirx Pharmaceutical Usa Llc Composiciones cosméticas y tópicas que comprenden cannabigerol y cannabidiol
US20160250270A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
JP6360614B2 (ja) * 2015-03-02 2018-07-18 久光製薬株式会社 貼付剤
EP3267875A4 (fr) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Système d'entrée d'état de manque et de support
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
CA2995418A1 (fr) * 2015-08-11 2017-02-16 KannaInnovations LLC Compositions topiques comprenant des hydroxyacides et des cannabinoides pour les soins de la peau
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
SG11201805570WA (en) 2015-12-30 2018-07-30 Corium Int Inc Systems and methods for long term transdermal administration
AU2017204945B2 (en) 2016-01-06 2022-11-10 Syqe Medical Ltd. Low dose therapeutic treatment
US11622929B2 (en) 2016-03-08 2023-04-11 Living Proof, Inc. Long lasting cosmetic compositions
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
CA3034004C (fr) 2016-08-29 2021-08-03 Canopy Growth Corporation Compositions hydrosolubles comprenant des cannabinoides purifies
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
WO2018129304A1 (fr) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Dispositifs et methodes d'administration transdermique de medicament
CA3053505A1 (fr) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations de cannabinoides pour le traitement du psoriasis
AU2018221880B2 (en) * 2017-02-15 2023-08-17 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
US20220323401A1 (en) * 2017-02-15 2022-10-13 Botanix Pharmaceuticals Ltd. Formulations of cannabinoids for the treatment of acne
WO2018148785A1 (fr) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations de cannabinoïdes pour le traitement de la dermatite et de maladies cutanées inflammatoires
WO2018148786A1 (fr) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations de cannabinoïdes pour le traitement de l'acné
WO2018148787A1 (fr) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations de cannabinoïdes pour le traitement du psoriasis
US20210128518A1 (en) * 2017-03-06 2021-05-06 Jack D. Korbutov Cannabinoid-containing dermatological compositions and methods using same
JP6801554B2 (ja) * 2017-03-29 2020-12-16 東洋インキＳｃホールディングス株式会社 皮膚貼付用粘着剤、皮膚用貼付剤、および剥離用シート状部材付き皮膚用貼付剤の製造方法
CN106943235A (zh) * 2017-03-31 2017-07-14 南阳医学高等专科学校 一种剖腹产术后护腹带
EP3681920B1 (fr) 2017-09-13 2025-06-25 Living Proof, Inc. Compositions cosmétiques longue durée
EP3681921A2 (fr) 2017-09-13 2020-07-22 Living Proof, Inc. Compositions de protection de couleur
WO2019079402A2 (fr) * 2017-10-17 2019-04-25 Life Tech Global, Llc Systèmes d'administration améliorés pour des fractions comprenant des combinaisons améliorées de cbd, formulations et chimères
AU2018370210B2 (en) 2017-11-20 2024-09-26 Living Proof, Inc. Properties for achieving long-lasting cosmetic performance
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
CN107997882A (zh) * 2017-12-07 2018-05-08 云南汉木森生物科技有限责任公司 一种具有抗菌消炎、止痛功效的卫生巾及其制作方法
EP3723738A1 (fr) * 2017-12-13 2020-10-21 Corium, Inc. Méthode de création de dépôt pendant l'administration transdermique de médicament
US11896560B2 (en) 2018-01-24 2024-02-13 Botanix Pharmaceuticals Ltd. Cannabinoid dosing regime for dermatitis and inflammatory skin conditions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) * 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
EP3784711A1 (fr) 2018-04-27 2021-03-03 Living Proof, Inc. Compositions cosmétiques longue durée
CA3101966A1 (fr) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Procedes et systemes d'administration de medicament
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
UY38480A (es) 2018-11-19 2020-06-30 Receptor Holdings Inc Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides
WO2020183350A1 (fr) * 2019-03-12 2020-09-17 Radient Technologies Innovations Inc. Kit de timbre transdermique avec des unités posologiques transdermiques
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4037663A1 (fr) 2019-10-03 2022-08-10 Starton Therapeutics, Inc. Administration transdermique de dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
US11355822B2 (en) * 2020-01-23 2022-06-07 Duracell U.S. Operations, Inc. Battery peel off assembly for exposing a safety feature comprising an aversive agent
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
US12109381B2 (en) 2020-08-26 2024-10-08 Babak Ghalili Cannabinoid and menthol transdermal delivery systems and methods
US11141404B1 (en) * 2020-11-18 2021-10-12 Anebulo Pharmaceuticals, Inc. Formulations and methods for treating acute cannabinoid overdose
CN113384558A (zh) * 2021-02-01 2021-09-14 深圳普洛美康材料有限公司 一种递送大麻活性物质的透皮贴剂
AU2022362107A1 (en) 2021-10-11 2024-05-02 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
US20030125659A1 (en) * 2000-05-25 2003-07-03 Wolfgang Fleischer Dosage of transdermal delivery systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125659A1 (en) * 2000-05-25 2003-07-03 Wolfgang Fleischer Dosage of transdermal delivery systems
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy

Also Published As

Publication number Publication date
WO2008024408A2 (fr) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008021394A3 (fr) Formulations pharmaceutiques d'agonistes cannabinoïdes et procédé d'utilisation
WO2008027442A3 (fr) Formulations pharmaceutiques orales anti-abus à base d'opioïdes et procédé d'utilisation
WO2008024490A3 (fr) Formulations pharmaceutiques à usage oral de cannabinoïdes dissuadant les abus et leur procédé d'utilisation
WO2008033351A3 (fr) Formulations multimode de libération prolongée et résistantes à l'abus
WO2007087452A3 (fr) Formulations à libération prolongée empêchant l'usage abusif et méthodes d'utilisation de celles-ci
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2007095043A3 (fr) Formulations pharmaceutiques
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
CL2008000507A1 (es) Preparacion regioespecifica de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroxi metil)-2- metil propionico, protegido con isopropilidencetal; y composicion farmaceutica que comprende a dicho compuesto.
MY146969A (en) Dpp iv inhibitor formulations
WO2007109604A3 (fr) Compositions pharmaceutiques
WO2008112164A3 (fr) Modulateurs de l'aldéhyde déshydrogénase-2 mitochondrial, et leurs procédés d'utilisation
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2008001200A3 (fr) Composition transdermique à stabilité de couleur améliorée
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
WO2008105383A1 (fr) Dérivé de pyrazole et son utilisation pour des objectifs médicaux
WO2008055068A3 (fr) Inhibiteurs de l'histone désacétylase
WO2007109523A3 (fr) Procédés de stabilisation de compositions instables de manière oxydative
WO2004009091A8 (fr) Agonistes des recepteurs x du foie
WO2007135562A3 (fr) Nouveaux dérivés d'hydroxyphényle et leurs applications biologiques
WO2008075201A3 (fr) Compositions d'épigallocatéchine-3-gallate destinées au traitement du cancer et à la chimioprotection
WO2005117895A8 (fr) Compositions contenant de la meloxicame
WO2008111296A1 (fr) Agent pharmaceutique pour la prévention et le traitement d'une maladie cutanée induite par une kératinisation accélérée
WO2005046689A3 (fr) Utilisation d’un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l’obesite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837213

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07837213

Country of ref document: EP

Kind code of ref document: A2